project id: TCGA-LUAD; case submitter id: TCGA-62-A46V; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; normal tumor genotype snp match: Yes; rna integrity number: 8.3; age at index: 78; days to birth: -28495; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1929; age at diagnosis: 28495; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage IB; ajcc pathologic t: T2; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 2199.0; icd 10 code: C34.3; last known disease status: not reported; morphology: 8255/3; primary diagnosis: Adenocarcinoma with mixed subtypes; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Lower lobe, lung; synchronous malignancy: No; tissue or organ of origin: Lower lobe, lung; tumor grade: Not Reported; year of diagnosis: 2007; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 1751; days to sample procurement: 0; initial weight: 100.0; portion submitter id: TCGA-62-A46V-01A-11; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 3.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 75.0;